> Detailanzeige

Laverty, Meghan; Crowcroft, Natasha; Bolotin, Shelly; Hawken, Steven; Wilson, Kumanan; Amirthalingam, Gayatri; Biringer, Anne; Cook, Jocelynn; Dubey, Vinita; Fakhraei, Romina; Halperin, Scott A.; Jamieson, Frances; Kwong, Jeffrey C.; Sadarangani, Manish; Sucha, Ewa; Walker, Mark C.; Fell, Deshayne B.

Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy
  • Beteiligte: Laverty, Meghan; Crowcroft, Natasha; Bolotin, Shelly; Hawken, Steven; Wilson, Kumanan; Amirthalingam, Gayatri; Biringer, Anne; Cook, Jocelynn; Dubey, Vinita; Fakhraei, Romina; Halperin, Scott A.; Jamieson, Frances; Kwong, Jeffrey C.; Sadarangani, Manish; Sucha, Ewa; Walker, Mark C.; Fell, Deshayne B.
  • Erschienen: American Academy of Pediatrics (AAP), 2021
  • Erschienen in: Pediatrics
  • Sprache: Englisch
  • DOI: 10.1542/peds.2020-042507
  • ISSN: 0031-4005; 1098-4275
  • Schlagwörter: Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title /> </jats:sec> <jats:sec> <jats:title>BACKGROUND AND OBJECTIVES:</jats:title> <jats:p>Maternal immunization with tetanus, diphtheria, and acellular pertussis vaccine (Tdap) is routinely recommended in many countries as a strategy to protect young infants against severe pertussis infection; few studies have assessed whether prenatal exposure to the vaccine is associated with any longer-term adverse health effects in children. We evaluated the long-term safety of exposure to Tdap vaccination during pregnancy.</jats:p> </jats:sec> <jats:sec> <jats:title>METHODS:</jats:title> <jats:p>Population-based retrospective cohort study conducted in Ontario, Canada using multiple linked province-wide health administrative databases. All live births between April 2012 and March 2017 were included, and children were followed for up to 6 years to ascertain study outcomes. Children exposed to prenatal Tdap were propensity score matched to unexposed children at a 1:5 ratio. Tdap vaccination during pregnancy was ascertained by using vaccine-specific fee codes. Immune-related (infectious diseases, asthma) and nonimmune-related (neoplasm, sensory disorders) outcomes and a nonspecific morbidity outcome (urgent or inpatient health service use) were evaluated from birth to end of follow-up.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS:</jats:title> <jats:p>Of 625 643 live births, 12 045 (1.9%) were exposed to Tdap in utero. There were no significant increased risks of adverse childhood outcomes and prenatal Tdap exposure; however, we observed inverse associations (adjusted incidence rate ratio [95% confidence interval]) with upper respiratory infections (0.94 [0.90–0.99]), gastrointestinal infections (0.85 [0.79–0.91]), and urgent and inpatient health service use (0.93 [0.91–0.96]).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS:</jats:title> <jats:p>Exposure to Tdap vaccination in pregnancy was not associated with any increased risk of adverse health outcomes in early childhood, supporting the long-term safety of Tdap administration in pregnancy.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang